Estimated Time
1.00 hour
Release Date
Sep 28, 2023
Expiration Date
Sep 27, 2024
New and emerging advancements in the treatment of follicular lymphoma (FL) are on the horizon. Are you and your clinical teams up for the challenge of testing your skill in applying the latest clinical evidence to these groundbreaking therapies? This independent satellite symposium is an engaging learning experience, where you'll have the chance to compete against your colleagues in complex clinical cases of follicular lymphoma. Tune into our panel of experts as they discuss:
- Prognostic tools in evaluating and managing patients with FL, empowering you to make well-informed decisions about prognosis to tailor treatment plans accordingly
- The latest clinical evidence surrounding new and emerging therapies, differentiated by mechanisms of action, efficacy, and safety profiles, to optimize treatment outcomes
- Treatment selection for patients with relapsed/refractory FL, considering crucial factors such as prior therapy history, disease characteristics, and individual patient factors
This independent satellite symposium is derived from the Society of Hematologic Oncology 2023 Annual Meeting, originally held on September 8, 2023.
Speakers
Krish Patel, MD
Director, Lymphoma Program
Director, Hematologic Malignancies and Cellular Therapy
Center for Blood Disorders and Cellular Therapy
Swedish Cancer Institute
Seattle, WA
Krish Patel, MD is a clinical investigator, Director of the Lymphoma Program, and Director of Hematologic Malignancies and Cellular Therapy at the Swedish Cancer Institute (SCI) in Seattle, Washington. Dr. Patel completed his medical school, residency, and hematology and oncology fellowship training at Duke University School of Medicine where he served as a Chief Resident in Internal Medicine. In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL. In 2019, he was appointed as the Director of the Lymphoma Program at SCI to help continued development of the program’s clinical standards for lymphoma care, assist in the programmatic expansion of cell therapy services, and to help shape the continued growth of the lymphoma program’s clinical research endeavors.
In early 2022, Dr. Patel was named the Director of Hematologic Malignancies and Cellular Therapy to oversee the continued growth of SCI’s clinical and research programs in all hematologic diseases and broader strategy in growth of cell therapy, including applications of cellular therapy in solid tumor malignancies.
Clinically, Dr. Patel specializes in all aspects of care of patients with lymphomas and CLL and is a specialist in the therapeutic use of cellular and non-cellular immunotherapies.He has a specific research focus in the early stage development of novel targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies.He is a principal investigator for numerous therapeutic clinical trials at SCI, with a focus on phase I and II studies in lymphomas, CLL, and cellular therapies. Dr. Patel is also a member of the Paul G. Allen Research Center at SCI, serving as a co-founding member of the Center for Immuno-oncology.
Adrienne Phillips, MD, MPH
Director, Cell Therapy and Bone Marrow Transplantation
Associate Professor of Medicine
RWJBarnabas Health
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, USA
Dr. Phillips is the Director of Cell Therapy and Bone Marrow Transplantation at RWJBarnabas Health and an Associate Professor of Medicine at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey, USA. She received her Medical Degree with honors from Brown University, and Master of Public Health from Harvard University. Dr. Phillips completed both her residency in Internal Medicine and fellowship in Hematology-Oncology at New York Presbyterian Hospital-Columbia. Her clinical and translational research focus is on treating patients with HTLV-Related Adult T-Cell Leukemia Lymphoma (ATLL) through stem cell transplantation. Dr. Phillips has co-authored numerous publications in journals including Cancer, Journal of Blood Medicine, and Leukemia and Lymphoma. She is a Member of the American Society of Clinical Oncology, the American Society of Hematology, and the National Medical Association. Dr. Phillips has been awarded the American Society of Hematology’s esteemed Harold Amos Medical Faculty Career
Tycel Phillips, MD
Associate Professor of Medicine
City of Hope
Duarte, CA
Cancer care is a sort of personal mission for Tycel Phillips, M.D. As a teen, he saw how pancreatic cancer affected his grandmother and decided to follow her example of service and make his career helping others as a physician. When he was a medical resident, he lost his mother to breast cancer; her experience with chemotherapy inspired him to pursue research into treatments that are less toxic for patients. His approach to patients is to listen first to understand their needs and develop the most beneficial treatment plan.
Dr. Phillips earned his medical degree from Rush University, followed by a residency in internal medicine at the John H. Stroger Jr. Hospital of Cook County in Chicago. His fellowship training in oncology/hematology took place at University Hospitals in Cleveland. Before joining City of Hope, he was a clinical associate professor at the University of Michigan, where he was appointed the Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation.
Leading clinical trials into new targeted therapies is a vital part of Dr. Phillips’ work. He has published over 40 peer-reviewed studies and attracted dozens of research grants.
Away from work, Dr. Phillips likes to read, ride his bicycle with his children, exercise and travel.
Accreditation and Disclosure Information
Target Audience
This activity is intended for hematologic oncology physicians, nurses, pharmacists, and advanced practice clinicians who provide care for individuals with hematologic malignancies, especially follicular lymphoma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Apply prognostic tools to the evaluation and management of patients with FL, including patients with hallmarks of aggressive disease
- Compare and contrast mechanisms of action, efficacy data, and toxicity profiles for new and emerging therapies, including for third-line and later treatment settings in FL
- Select therapies for patients with RR FL in consideration of prior therapy, disease factors, patient factors, and treatment goals
Program Agenda
- Standard approaches to care in FL and implications of prognostic markers
- The latest clinical evidence and guideline recommendations for treatment decision-making in FL and common TRAEs (treatment-related adverse events)
- Patient-related factors that play an important role in access to novel therapies for FL and improved outcomes
- Q&A with Faculty
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
ECMEC® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMA-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-23-083-H01-P
Type of Activity: Application
Support Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
This activity is jointly provided by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Krish Patel, MD
Director, Lymphoma Program
Director, Hematologic Malignancies and Cellular Therapy
Center for Blood Disorders and Cellular Therapy
Swedish Cancer Institute
Seattle, WA
Krish Patel, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Fate Therapeutics, Genentech, Kite, Lilly, MEI Pharma, MorphoSys, Nurix, Pharmacyclics, Pfizer, Xencor
Research Grant: AbbVie, Caribou, Fate Therapeutics, Genentech, Kite, Lilly, Nurix, Pharmacyclics, Pfizer, Xencor
Speakers’ Bureau: AstraZeneca, Bristol Myers Squibb, Kite
Planner/Presenter
Adrienne Phillips, MD, MPH
Director of Cell Therapy and Bone Marrow Transplantation, Northern Regions, RWJ Barnabas Health and
Rutgers Cancer Institute of NJ
New York, NY
Adrienne A. Phillips, MD, MPH has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Tycel Phillips, MD
Associate Professor of Medicine
City of Hope
Duarte, CA
Tycel Phillips, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Epizyme, Eli Lily, Genentech, Genmab, Gilead, Incyte, Pharmacyclics, TG Therapeutics
Research Grant: AbbVie, Genentech
Other: Strategic Council: Epizyme, Genmab; Scientific Committee: Genmab, Genentech, Merck
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Leukemia & Lymphoma Society, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Planner Lauren Berger, MPH
The Leukemia & Lymphoma Society
Lauren Berger, MPH has a financial interest/relationship or affiliation in the form of:
Stock Ownership: Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians requesting ABIM MOC credit, it is required that you:
- Use the same email address that you logged on
- Provide your ABIM ID number and DOB (MM/DD)
- Participate in the Kahoot! component of the case-study
- Complete the activity evaluation
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.